1. Persistent Circulating Tumor Cells At One Year After Oncologic Resection Of Pancreatic Cancer Predict Recurrence.
- Author
-
Wolfgang, C.L., Ding, D., Hasanain, A., Oosten, F.V., Gemenetzis, G., Groot, V., Tenior, J., Javed, A.A., Wright, M., Yu, J., Cameron, J., Weiss, M., Burns, W.R., Burkhart, R., Zheng, L., and He, J.
- Subjects
- *
CANCER relapse , *PANCREATIC cancer , *ONCOLOGIC surgery , *PROGNOSIS , *ADJUVANT chemotherapy - Abstract
B Presenter: b Ding Ding MD, ScM | Johns Hopkins University School of Medicine B Background: b Circulating tumor cell (CTC) subtypes have been used as new biomarkers to predict early or late recurrence and response to treatment for pancreatic cancer. Both epithelial CTC (eCTC) and epithelial/mesenchymal CTC (mCTC) subtypes were used to predict recurrence from the CTC testing time within 9-15months after surgery. On multi-variable cox model including pathological covariates, neo-adjuvant, and adjuvant chemotherapy status, high eCTCs was a risk factor for recurrence since date of CTC testing(Hazard Ratio = 4.41; 95% CI [1.13, 17.23]; p=0.033). [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF